NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis $5.52 +0.01 (+0.11%) As of 12:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aldeyra Therapeutics Stock (NASDAQ:ALDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aldeyra Therapeutics alerts:Sign Up Key Stats Today's Range$5.44▼$5.5850-Day Range$4.81▼$5.8952-Week Range$1.14▼$7.20Volume196,898 shsAverage Volume1.12 million shsMarket Capitalization$330.41 millionP/E RatioN/ADividend YieldN/APrice Target$9.50Consensus RatingHold Company Overview Aldeyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need. The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage. Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.AI Generated. May Contain Errors. Read More Aldeyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreALDX MarketRank™: Aldeyra Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 623rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingAldeyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAldeyra Therapeutics has a consensus price target of $9.50, representing about 72.2% upside from its current price of $5.52.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aldeyra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aldeyra Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.98% of the outstanding shares of Aldeyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 1.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.98% of the outstanding shares of Aldeyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 1.70%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.89 News SentimentAldeyra Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows2 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,676.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aldeyra Therapeutics' insider trading history. Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALDX Stock News HeadlinesAldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | businesswire.comAldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites ...August 28, 2025 | uk.finance.yahoo.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 7 at 2:00 AM | StockEarnings (Ad)Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal LymphomaAugust 28, 2025 | businesswire.comJonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9August 24, 2025 | finance.yahoo.comJonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9August 23, 2025 | insidermonkey.comAldeyra Therapeutics Gains FDA Fast Track for ADX-2191August 19, 2025 | msn.comAldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis PigmentosaAugust 19, 2025 | businesswire.comSee More Headlines ALDX Stock Analysis - Frequently Asked Questions How have ALDX shares performed this year? Aldeyra Therapeutics' stock was trading at $4.99 at the beginning of 2025. Since then, ALDX stock has increased by 10.5% and is now trading at $5.5160. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) released its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings8/07/2025Today10/07/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALDX CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees10Year Founded2004Price Target and Rating Average Price Target for Aldeyra Therapeutics$9.50 High Price Target$10.00 Low Price Target$9.00 Potential Upside/Downside+72.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.63% Return on Assets-50.61% Debt Debt-to-Equity RatioN/A Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book4.63Miscellaneous Outstanding Shares59,900,000Free Float54,805,000Market Cap$330.29 million OptionableOptionable Beta0.83 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ALDX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.